Nuvation Bio (NUVB) has a profit margin of -67.38%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for NUVB is -67.38% as of September 2026. That compares with -813.07% in the prior-year period — up 91.7% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Nuvation Bio's historical trend and sector peers before judging valuation or financial health.
Over the past year, NUVB's profit margin moved from -813.07% to -67.38% — a 91.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nuvation Bio's valuation or profitability profile.
Against Healthcare companies, NUVB currently prints -67.38% for profit margin, while the sector average sits near 17.63%. That is roughly 482.2% below the sector mean. Large gaps often invite a closer look at Nuvation Bio's growth, margins, and balance sheet.
Profit Margin shows how effectively Nuvation Bio converts resources into returns. At -67.38%, NUVB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -813.07% in the prior-year period — up 91.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NUVB's profit margin (-67.38%), review year-over-year change from -813.07%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.